The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | AI advancements at ASCO 2024: transformative impact on cancer diagnosis, treatment, & research
Ravi Bharat Parikh, MD, MPP, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, reflects on the transformative impact of artificial intelligence (AI) showcased at the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. Dr Parikh highlights the significant advancements in AI applications across various cancers, including lung, prostate, and breast cancer. He emphasizes that high-quality AI models are now not only being developed but also prospectively and externally validated. This progress signals a promising future for integrating AI into patient diagnosis, treatment planning, and drug discovery. Dr Parikh notes that the advancements presented at the meeting underscore how close we are to realizing the full potential of AI technologies in oncology, marking a significant step forward in cancer care and research. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
